Fuminori Yoshida remarks

SymBio 's dream

We aim to develop new drugs that allow us to see the patient's face, and in particular, we aim to develop new drugs that focus on diseases that are particularly difficult to treat.

The mission of pharmaceutical manufacturers, needless to say, is nothing other than "developing new drugs for unmet medical needs. However, the current reorganization of the pharmaceutical industry toward megapharma and global orientation, which is undergoing a major structural change, has led to the creation of the so-called "Underserved Therapeutic Areas" by abandoning research and development for the reason that it is unprofitable due to low patient numbers.
SymBio Our mission is to shed light on "Underserved Therapeutic Areas" by developing and providing new drugs to the medical community that are truly needed by the medical community, at least in terms of the number of patients. Under the philosophy of "to co-create and to co-exist", we will open a new path to new drug development by connecting five groups: physicians, scientists, regulators, and investors, with the patients at the center, and through the driving force generated by these groups.
We are a pharmaceutical company without a laboratory. We have a unique network to search for new drug candidates with high medical needs from bio-ventures around the world that are conducting basic research, and we have the ability to select "new drug candidates" through co-creation with leading physicians and researchers who participate as a Scientific Advisory Board, and to develop and commercialize them quickly. In other words, we are building the ability to quickly develop and commercialize new drug candidates. In other words, the value of SymBio Pharmaceuticals lies in its ability to bring together the wisdom of basic and clinical medicine from around the world.
We provide new drugs that patients and the medical community demand, and use the profits generated to further expand the fields of disease and therapeutic areas. We will also fulfill our social responsibility by building a new cyclical model in which a portion of profits is returned to society in the form of a "Giving Back Program" for research on intractable diseases, patient care, and the training of the next generation of researchers.
To grow not through competition, but through Symbiosis.
This is what we are aiming for as a new type of pharmaceutical manufacturer.